Vinay Prasad

Associate Professor

  • 3094 Citations
  • 28 h-Index
20092019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 2009 2019

2019
10 Citations (Scopus)

A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals

Herrera-Perez, D., Haslam, A., Crain, T., Gill, J., Livingston, C., Kaestner, V., Hayes, M., Morgan, D., Cifu, A. S. & Prasad, V., Jun 11 2019, In : eLife. 8

Research output: Contribution to journalArticle

Open Access
New England
American Medical Association
Medicine
Cardiovascular Diseases
Randomized Controlled Trials
3 Citations (Scopus)
Drug Approval
Quality Control
Randomized Controlled Trials
Standard of Care
Antineoplastic Agents
14 Citations (Scopus)
United States Food and Drug Administration
Biomarkers
Drug Approval
Pharmaceutical Preparations
Neoplasms
1 Citation (Scopus)

A reality check of the accelerated approval of immune-checkpoint inhibitors

Gill, J. & Prasad, V., Jan 1 2019, (Accepted/In press) In : Nature Reviews Clinical Oncology.

Research output: Contribution to journalComment/debate

Open Access
Outcome Assessment (Health Care)
Neoplasms
Research Personnel
Cross-Sectional Studies
Clinical Trials
Conflict of Interest
Glioblastoma
Neoplasms
Equipment and Supplies
Registries

A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda

Luo, J., Nishikawa, G. & Prasad, V., Sep 4 2019, In : Journal of Cancer Research and Clinical Oncology. 145, 9, p. 2303-2311 9 p.

Research output: Contribution to journalReview article

Meta-Analysis
Monoclonal Antibodies
Neoplasms
Ligands
Pharmaceutical Preparations
23 Citations (Scopus)

A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology

Haslam, A., Hey, S. P., Gill, J. & Prasad, V., Jan 1 2019, In : European Journal of Cancer. 106, p. 196-211 16 p.

Research output: Contribution to journalReview article

Meta-Analysis
Validation Studies
Biomarkers
Survival
Randomized Controlled Trials
2 Citations (Scopus)

Cancer screening: A modest proposal for prevention

Kim, M. S., Nishikawa, G. & Prasad, V., Mar 1 2019, In : Cleveland Clinic journal of medicine. 86, 3, p. 157-160 4 p.

Research output: Contribution to journalComment/debate

Open Access
Early Detection of Cancer

Case Reports in the Age of Twitter

Cifu, A. S., Vandross, A. L. & Prasad, V., Jan 1 2019, In : American Journal of Medicine.

Research output: Contribution to journalEditorial

Open Access
1 Citation (Scopus)

Characteristics of Public Comments Submitted to State Health Technology Assessment Programs in Oregon and Washington

Ahn, R., Herrera-Perez, D. & Prasad, V., Jan 1 2019, (Accepted/In press) In : JAMA Internal Medicine.

Research output: Contribution to journalLetter

Biomedical Technology Assessment

Concerning survival signal for eltrombopag in MDS/AML

Tao, D. & Prasad, V., Jan 1 2019, (Accepted/In press) In : Leukemia and Lymphoma.

Research output: Contribution to journalLetter

3 Citations (Scopus)

Confirmatory Trials for Drugs Approved on a Single Trial

Haslam, A. & Prasad, V., Jun 1 2019, In : Circulation. Cardiovascular quality and outcomes. 12, 6, p. e005494

Research output: Contribution to journalArticle

Valsartan
Drug Approval
Fish Oils
Pharmaceutical Preparations

Essere un medico conservativo

Mandrola, J., Cifu, A., Prasad, V. & Foy, A., Apr 1 2019, In : Recenti Progressi in Medicina. 110, 4, p. 156-158 3 p.

Research output: Contribution to journalReview article

6 Citations (Scopus)

Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials

Chen, E. Y., Joshi, S. K., Tran, A. & Prasad, V., Jan 1 2019, In : JAMA Internal Medicine.

Research output: Contribution to journalArticle

Biomarkers
Clinical Trials
United States Food and Drug Administration
Drug Approval
Survival
29 Citations (Scopus)
Open Access
Immunotherapy
Pharmaceutical Preparations
Neoplasms
United States Food and Drug Administration
Melanoma

Improving the design of pivotal clinical trials

Prasad, V., Mar 1 2019, In : Clinical Advances in Hematology and Oncology. 17, 3, p. 150-152 3 p.

Research output: Contribution to journalArticle

Clinical Trials

Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice?

Chapa, J., Haslam, A. & Prasad, V., Jun 1 2019, In : Mayo Clinic Proceedings. 94, 6, p. 951-956 6 p.

Research output: Contribution to journalShort survey

Open Access
Population Characteristics
Early Detection of Cancer

Making adjuvant therapy decisions with uncertain data

Gyawali, B. & Prasad, V., Mar 1 2019, In : Annals of Oncology. 30, 3, p. 361-364 4 p.

Research output: Contribution to journalReview article

Open Access
Therapeutics

Medical reversals in low- and middle-income countries

Haslam, A., Prasad, V. & Livingston, C., Jan 1 2019, (Accepted/In press) In : International Journal of Health Planning and Management.

Research output: Contribution to journalArticle

Delivery of Health Care
Health Resources
Evidence-Based Practice
Budgets
Septic Shock
3 Citations (Scopus)

Metastasis-free survival in prostate cancer: Faster drug approvals, better drugs?

Parikh, R. B. & Prasad, V., Feb 1 2019, In : Journal of Clinical Oncology. 37, 4, p. 266-268 3 p.

Research output: Contribution to journalArticle

Drug Approval
Prostatic Neoplasms
Neoplasm Metastasis
Pharmaceutical Preparations

Multiplicity in oncology randomised controlled trials: a threat to medical evidence?

Prasad, V. & Booth, C. M., Dec 2019, In : The Lancet Oncology. 20, 12, p. 1638-1640 3 p.

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Real-world Evidence - What Does It Really Mean?

Nabhan, C., Klink, A. & Prasad, V., Jan 1 2019, In : JAMA Oncology.

Research output: Contribution to journalReview article

1 Citation (Scopus)

Registration studies — when should patients be deemed ineligible for aggressive therapy?

Cook, R. J., Gill, J. & Prasad, V., Jan 1 2019, In : Nature Reviews Clinical Oncology.

Research output: Contribution to journalComment/debate

Therapeutics

Reply to C.J. Sweeney et al

Parikh, R. B. & Prasad, V., Jan 1 2019, In : Journal of Clinical Oncology. 37, 19, p. 1680-1681 2 p.

Research output: Contribution to journalLetter

1 Citation (Scopus)

Should Evidence Come with an Expiration Date?

Greene, P., Prasad, V. & Cifu, A., Jan 1 2019, In : Journal of general internal medicine.

Research output: Contribution to journalArticle

Testing for blinding in sham-controlled studies for procedural interventions: The third-party video method

Gill, J. & Prasad, V., Mar 11 2019, In : CMAJ. 191, 10, p. E272-E273

Research output: Contribution to journalComment/debate

Open Access
Latent Tuberculosis
Delivery of Health Care
2 Citations (Scopus)

The Case for Being a Medical Conservative

Mandrola, J., Cifu, A., Prasad, V. & Foy, A., Jan 1 2019, In : American Journal of Medicine.

Research output: Contribution to journalEditorial

Open Access
Evidence-Based Medicine
Clinical Decision-Making

The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab

Kim, M. S. & Prasad, V., Jan 1 2019, (Accepted/In press) In : JAMA Internal Medicine.

Research output: Contribution to journalLetter

Clinical Trials
eculizumab

The Reply

Mandrola, J., Cifu, A., Prasad, V. & Foy, A., Sep 2019, In : American Journal of Medicine. 132, 9, p. e719

Research output: Contribution to journalLetter

Where Does the Blame for High Health Care Costs Go? An Empirical Analysis of Newspaper and Journal Articles Criticizing Health Care Costs

Haslam, A., Crain, T., Gill, J., Herrera-Perez, D. & Prasad, V., Jan 1 2019, (Accepted/In press) In : American Journal of Medicine.

Research output: Contribution to journalArticle

Newspapers
Health Care Costs
PubMed
Delivery of Health Care
Publications
2018
2 Citations (Scopus)

Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy - Reply

Hernandez, I., Prasad, V. & Gellad, W. F., Jan 1 2018, (Accepted/In press) In : JAMA oncology.

Research output: Contribution to journalArticle

T-Cell Antigen Receptor
Immunotherapy
Costs and Cost Analysis
5 Citations (Scopus)

A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature

Nishikawa, G., Luo, J. & Prasad, V., Sep 1 2018, In : European Journal of Cancer. 101, p. 143-151 9 p.

Research output: Contribution to journalArticle

Pharmaceutical Preparations
Neoplasms
History
Drug Therapy
Conflict of Interest

Addendum: Low-value approvals and high prices might incentivize ineffective drug development

Prasad, V., McCabe, C. & Mailankody, S., Jan 1 2018, (Accepted/In press) In : Nature Reviews Clinical Oncology.

Research output: Contribution to journalArticle

Pharmaceutical Preparations
Costs and Cost Analysis
3 Citations (Scopus)

A pooled analysis of published, basket trials in cancer medicine

Hazim, A. & Prasad, V., Sep 1 2018, In : European Journal of Cancer. 101, p. 244-250 7 p.

Research output: Contribution to journalArticle

Medicine
Neoplasms
Fallopian Tube Neoplasms
Thymus Neoplasms
Seminoma
1 Citation (Scopus)

Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?

Shanbhag, S. & Prasad, V., Nov 1 2018, In : European Journal of Cancer. 104, p. 252-253 2 p.

Research output: Contribution to journalLetter

Hodgkin Disease
Costs and Cost Analysis
cAC10-vcMMAE
26 Citations (Scopus)

Cancer drugs approved based on biomarkers and not tumor type - FDA approval of pembrolizumab for mismatch repair-deficient solid cancers

Prasad, V., Kaestner, V. & Mailankody, S., Feb 1 2018, In : JAMA oncology. 4, 2, p. 157-158 2 p.

Research output: Contribution to journalShort survey

DNA Mismatch Repair
Tumor Biomarkers
Pharmaceutical Preparations
Neoplasms
pembrolizumab
3 Citations (Scopus)

Choice of control group in randomised trials of cancer medicine: are we testing trivialities?

Tao, D. & Prasad, V., Sep 1 2018, In : The Lancet Oncology. 19, 9, p. 1150-1152 3 p.

Research output: Contribution to journalComment/debate

Medicine
Control Groups
Neoplasms
5 Citations (Scopus)

Concerns about the approval of nusinersen sodium by the US food and drug administration

Gerrity, M. S., Prasad, V. & Obley, A. J., Jun 1 2018, In : JAMA Internal Medicine. 178, 6, p. 743-744 2 p.

Research output: Contribution to journalComment/debate

United States Food and Drug Administration
Sodium
Cardiovascular Agents
Drug Therapy
Pharmaceutical Preparations
LCZ 696
1 Citation (Scopus)

Cost-effectiveness of nusinersen for spinal muscular atrophy: Reply

Prasad, V., Jul 1 2018, In : JAMA Pediatrics. 172, 7, p. 701-702 2 p.

Research output: Contribution to journalLetter

Spinal Muscular Atrophy
Cost-Benefit Analysis
1 Citation (Scopus)

Crossover is not associated with faster trial accrual

Chen, E. Y. & Prasad, V., Mar 1 2018, In : Annals of Oncology. 29, 3, p. 776-777 2 p., mdx821.

Research output: Contribution to journalLetter

4 Citations (Scopus)
Stroke
Myocardial Infarction
Clinical Trials
Neoplasm Metastasis
Recurrence
19 Citations (Scopus)

Direct-to-consumer genetic testing the implications of the US FDA's first marketing authorization for BRCA mutation testing

Gill, J., Obley, A. J. & Prasad, V., Jun 19 2018, In : JAMA - Journal of the American Medical Association. 319, 23, p. 2377-2378 2 p.

Research output: Contribution to journalReview article

Genetic Testing
Marketing
Mutation
Direct-To-Consumer Screening and Testing
LCZ 696

Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission

Hilal, T. & Prasad, V., Jan 1 2018, (Accepted/In press) In : Nature Reviews Clinical Oncology.

Research output: Contribution to journalArticle

Residual Neoplasm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Lymphocytes
Biomarkers
Pharmaceutical Preparations
50 Citations (Scopus)

Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology

Marquart, J., Chen, E. Y. & Prasad, V., Aug 1 2018, In : JAMA oncology. 4, 8, p. 1093-1098 6 p.

Research output: Contribution to journalArticle

Genome
Neoplasms
United States Food and Drug Administration
Therapeutics
Pharmaceutical Preparations
6 Citations (Scopus)

Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings

Hayes, M. J. & Prasad, V., Mar 1 2018, In : Hastings Center Report. 48, 2, p. 10-13 4 p.

Research output: Contribution to journalArticle

Pharmacy and Therapeutics Committee
Conflict of Interest
conflict of interest
Advisory Committees
drug
9 Citations (Scopus)

Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: Retrospective observational study

Wagner, J., Marquart, J., Ruby, J., Lammers, A., Mailankody, S., Kaestner, V. & Prasad, V., Jan 1 2018, In : BMJ (Online). 360, k668.

Research output: Contribution to journalArticle

United States Food and Drug Administration
Observational Studies
Retrospective Studies
Guidelines
Pharmaceutical Preparations